期刊文献+

补肾强督方对50例强直性脊柱炎继发骨质疏松症患者血清骨保护素、骨密度及骨代谢的影响 被引量:15

Effect of Bushen Qiangdu Formula on Serum Osteoprotegerin,Bone Mineral Density and Bone Metabolism of 50 Patients of Osteoporosis with Ankylosing Spondylitis
原文传递
导出
摘要 目的研究补肾强督方对强直性脊柱炎(AS)继发骨质疏松症患者的疗效及机理。方法应用补肾强督方治疗50例AS骨质疏松症患者6个月,检测患者治疗前后血清骨保护素(OPG)、骨密度,血清骨钙素(BGP)、降钙素(H-CT)、甲状旁腺激素(PTH)、骨特异性碱性磷酸酶(BAP)、型胶原羧基端延长肽(CICP)、尿脱氧吡啶啉(DPD)、型胶原交联C末端肽(CTX)、血沉(ESR)、C-反应蛋白(CRP),观察治疗前后患者功能指数(BASFI)、病情活动指数(BASDI)及症状、体征的变化。结果治疗后患者血清OPG水平、骨密度、BGP、BAP显著升高(P<0.05或P<0.01),DPD、CTX显著下降(P<0.01);ESR、CRP、BASFI、BASDAI、症状、体征等明显改善。结论补肾强督方可以提高AS患者的血清OPG、骨密度水平,调节AS患者的骨代谢及免疫水平。 Objective To study the effect of and its mechanism Bushen Qiangdu Formula (Formula for reinforcing kidney and strengthening spine) on patients with osteoporosis induced by ankylosing spondylitis (AS). Methods All 50 AS patients with osteoporosis were treated with Bushen Qiangdu Formula for six months. Before and after treatment, the observation term includes serum osteoprotegerin (OPG), bone mineral density (BMD), serum boneglaprotein (BGP), calcitonin (H-CT), parathyroid hormone (PTH), bone-specific alkaline phosphatase (BAP), collagen I carboxyl-terminal-prolonging peptides (CICP), urine deoxidation pydidinoline (DPD), C-telopeptide of type Ⅰ collagen (CTX-Ⅰ), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), Bath AS Function Index (BASFI), Bath AS dynamic Index (BASDI), and symptoms and signs. Resuits After treatment, the serum OPG significantly increased (P〈0.05), BMD greatly raised (P〈0.05 or P〈0.01), BGP and BAP obviously up-regulated (P〈0.05 or P〈0.01), and their DPD and CTX significantly decreased (P〈0.01); and got their ESR, CRP, BASFI, BASDI, and symptoms and signs tremendously improved. Conclusion Bushen Qiangdu Formula is effective to increase the serum OPG and BMD, and regulate the bone metabolism and immunity of AS patients.
出处 《中医杂志》 CSCD 北大核心 2009年第12期1079-1083,共5页 Journal of Traditional Chinese Medicine
关键词 补肾强督方 强直性脊柱炎 骨保护素 骨密度 骨代谢 Bushen Qiangdu Formula (Formula for reinforcing kidney and strengthening spine) Ankylosing spondylitis Osteoprotegerin Bone mineral density Bone Metabolism
  • 相关文献

参考文献23

  • 1Toussirot E,Ricard-Blum S,Dumoulin G, et al. Relationship between urinary pyridinium cross-links, disease actibity and disease subsets of ankylosing spondylitis[J]. Rheumatology (Oxford), 1999,38(1):21 - 27.
  • 2Rauner M, Sipos W, Pietschmann P. Osteoimmunology[J]. Int Arch Allergy Immunol, 2007,143 (1) : 31 - 48.
  • 3Haynes DR ,Barg E,Crotti TN ,et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis,spondyloarthropathies and osteoarthritis and normal controls[J]. Rheumatology (Oxford), 2003,42 (1) : 123 - 134.
  • 4赵伟,黄烽.护骨素在强直性脊柱炎外周关节骨质破坏病理机制中的作用[J].中华风湿病学杂志,2005,9(6):329-333. 被引量:17
  • 5van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria[J]. Arthritis Rheum, 1984, 27(4): 361-368.
  • 6中国人骨质疏松症建议诊断标准(第二稿)[J].中国骨质疏松杂志,2000,6(1):1-3. 被引量:1237
  • 7Calin A,Garrett S,Whitelock H,et al. A new approach to defining functional ability in ankylosing spondylitis:the development of the Bath Ankylosing Spondylitis Functional Index [J]. J Rheumatol, 1994,21 (12) : 2281 - 2285.
  • 8Garrett S, Jenkinson T,Kennedy LG,et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index[J]. J Rheumatol, 1994,21 (12) : 2286 - 2291.
  • 9Mitra D, Elvins DM, Collins AJ. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures [J]. J Rheumatol, 1999,26(10) :2201 - 2204.
  • 10孔维萍,阎小萍,秦林林,张卫,马海波,葛崇华,颜珏.强直性脊柱炎并骨质疏松97例临床观察[J].中医正骨,2005,17(11):3-6. 被引量:17

二级参考文献45

  • 1曾庆馀,黄少弼,陈韧,周修国,肖征宇,许敬才,林秋强,谢素和.汕头地区风湿病流行病学调查10年小结[J].中华内科杂志,1997,36(3):193-197. 被引量:33
  • 2Toussirot E, Ricard-Blum S, Dumoulin G, et al. Relationship between urinary pyridinium cross-links, disease activity and disease suhsets of ankylosing spondylitis. Rheumatol (Oxford), 1999, 38:21-27.
  • 3Toussirot E, Michel F, Auge B, et al. Bone mass, body composition and bone ultrasound measurements in ankylosing spondylitis.Arthritis Rheum, 1999, 42(Suppl): 356.
  • 4Bernecker PM, Aringer M, et al. Ankylosing spondylitis,arthritis, and reactive arthritis show increased bone rebut differ with regard to bone formation. J Rheumatol,2002,29:1430-1436.
  • 5Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol, 2000, 27: 2295-3301.
  • 6Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am, 1998,24:697-736.
  • 7Bekker PJ, Holloway D, Nakanishi A, et al. Osteoprotegerin has potent and sustained anti-resorptive activity in postmenopausal women. J Bone Miner Res, 1999, 14(Suppl 1):1190.
  • 8Hotbauer LC, Khosla S, Dunstan CR, et al. The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res, 2000, 15: 2-12.
  • 9Mori H, Kitazawa R, Maeda S, et al. RANK ligand, RANK, and OPG expression in type Ⅱ collagen-induced arthritis mouse.Histochem Cell Biol, 2002, 117: 283-292.
  • 10Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.Arthritis Rheum, 2000, 43: 250-258.

共引文献1298

同被引文献208

引证文献15

二级引证文献156

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部